BUZZ-Cue Biopharma shares soar as interim clinical trial results for CUE-221 show positive outcomes

September 21 - ** Cue Biopharma (CUE.O) shares soared 28.9% in pre-market trading to $47.74

** The company announced positive results from mid-stage studies of CUE-221 for the treatment of urticaria

** The trial met the primary and key secondary endpoints for phase II

** Cue's second-quarter revenue more than doubled earlier this month (link)

** As of the previous session close, the share price is up more than 300% year to date

(To assist non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain errors or lack the required context, Reuters does not guarantee the accuracy of automated translated texts and provides them solely for readers’ convenience. Reuters accepts no liability for any damage or loss arising from the use of automated translation tools.)